Research ArticleMultimodal doxorubicin loaded magnetic nanoparticles for VEGF targeted theranostics of breast cancer
Graphical Abstract
Targeted therapy is one of the most advanced techniques in treatment of malignant tumors, but still it has some limitations, mostly associated with difficulties in development and clinical approbation of new tumor specific ligands. One of the approaches is to use already existing molecules as targeting moieties. In this study we present use of monoclonal antibodies to VEGF as effective ligand for doxorubicin loaded magnetic nanoparticles delivery for tumor therapy and diagnostics.
Section snippets
Materials
N-hydroxysuccinimide (NHS), 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), bovine serum albumin (BSA), 6-aminofluorescein, Tween-20, Triton X-100, Sepharose CL-4B, 4,6-diamidino-2-phenylindole (DAPI), nonspecific mouse immunoglobulins (IgG), phosphate buffer saline (PBS), dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich, USA. Monoamino terminated poly(ethylene glycol) hydrochloride (NH2-PEG-OH) was from Creative PEGworks, USA. Cyanine5 (Cy5) label was purchased from Lumiprobe
Synthesis and characterization of MNP
Thermal decomposition of iron (III) acetylacetonate has resulted in production of dark brown powder, which nicely dissolves in water at pH 9-11. After adsorption of BSA and stabilization of protein coating by crosslinking and PEGylation the samples were characterized by TEM and AFM (Figure 1) Presented image shows narrow distribution of iron oxide core of obtained MNP with average diameter 8±3 nm. Due to low contrast between elements with low molecular weight e.g. C, O, N on TEM we were not
Discussion
To provide active targeted delivery of anticancer drug and to increase its anti-tumor effectiveness it is needed to obtain nanocarrier with high specificity to cancer cells. As a nanocarrier we chose iron oxide magnetic nanoparticles, which are coated by BSA and PEG and conjugated with mAb VEGF. However during the process of synthesis the conjugation of antibodies by itself might disrupt their three dimensional structure or modify the binding site that will lead to loss of immunochemical
References (42)
- et al.
Targeted delivery of doxorubicin to breast cancer cells by magnetic LHRH chitosan bioconjugated nanoparticles
Int J Biol Macromol
(2016) - et al.
Combination of drug-conjugated SWCNT nanocarriers for efficient therapy of cancer stem cells in a breast cancer animal model
J Control Release
(2016) - et al.
Progress of drug-loaded polymeric micelles into clinical studies
J Control Release
(2014) - et al.
et all. VEGF-targeted magnetic nanoparticles for MRI visualization of brain tumor
Nanomedicine
(2015) - et al.
Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging
Adv Drug Deliv Rev
(2010) - et al.
Targeted cancer nanotherapy
Mater Today
(2005) - et al.
Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer
Cancer Lett
(2006) Doxil - The first FDA-approved nano-drug: Lessons learned
J Control Release
(2012)- et al.
Core-shell-corona doxorubicin-loaded superparamagnetic Fe3O4 nanoparticles for cancer theranostics
Colloids Surf B Biointerfaces
(2015) - et al.
Multidrug resistance in cancer: role of ATP–dependent transporters
Nat Rev Cancer
(2002)
Recent advances with liposomes as pharmaceutical carriers
Nat Rev Drug Discov
Dendrimers in drug research
Chem Soc Rev
Iron oxide MR contrast agents for molecular and cellular imaging
NMR Biomed
Superparamagnetic iron oxide nanoparticles: Magnetic nanoplatforms as drug carriers
Int J Nanomedicine
Biodegradation of magnetic nanoparticles in mouse liver from combined analysis of mössbauer and magnetization data
IEEE Trans Magn
Mössbauer evidence of 57Fe3O4 based ferrofluid biodegradation in the brain
Hyperfine Interact
Efficient cisplatin pro-drug delivery visualized with sub-100 nm resolution: Interfacing engineered thermosensitive magnetomicelles with a living system
Adv Mater Interfaces
Stimuli-responsive magnetic nanomicelles as multifunctional heat and cargo delivery vehicles
Langmuir
Mechanoresponsive system based on sub-micron chitosan-functionalized ferromagnetic disks
J Mater Chem
The Ligand Nanoparticle Conjugation Approach for Targeted Cancer Therapy
Curr Drug Metab
Targeted drug delivery in cancer therapy
Technol Cancer Res Treat
Cited by (55)
Riding the metal wave: A review of the latest developments in metal-based anticancer agents
2024, Coordination Chemistry ReviewsCancer chemotherapy resistance: Mechanisms and recent breakthrough in targeted drug delivery
2023, European Journal of PharmacologyInducing vascular normalization: A promising strategy for immunotherapy
2022, International ImmunopharmacologyCitation Excerpt :A number of nanoparticle-based delivery systems have been used to deliver siVEGF into tumors[134–136]. Alevtina S et al. demonstrated that doxorubicin-loaded VEGF-targeted magnetic nanoparticles increased median survival by 50 % in mice bearing 4T1 tumors[134]. Co-delivery of paclitaxel and siVEGF by smart nanoparticles can exert anti-tumor effects by inhibiting the formation and development of new blood vessels in tumor tissues[135].
Nano-targeting vascular remodeling in cancer: Recent developments and future directions
2022, Seminars in Cancer BiologyCitation Excerpt :Theranostics is an emerging field that combines diagnostic and therapeutic tools to optimize personalized treatment [156]. In this context, a method based on VEGF-targeted magnetic nanoparticles has been recently investigated in mice bearing breast adenocarcinoma, 4T1 cell line [157]. The intravenous administration of doxorubicin-loaded VEGF-targeted nanoparticles increased the survival rate up to 50%.
The role of imaging in targeted delivery of nanomedicine for cancer therapy
2022, Advanced Drug Delivery Reviews
This work was supported by Grant of President of Russian Federation (grant number MK-6371.2016.7), RSF grant 17-14-01316 (investigation of Dox loading) and grant of Ministry of Education and Science of the Russian Federation in the framework of Increase Competitiveness Program of NUST «MISiS» №K2-2015-071 (assessment of nanoparticles toxicity) and №K4-2017- 046 (assessment of MRI study).
Conflicts of interest: There are no conflicts to declare.
- 1
Both authors contributed equally.